CTOs on the Move


 
Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to pioneer new products with a mission to dramatically improve the lives of patients with severe autoimmune and inflammatory diseases who continue to suffer with high unmet medical needs.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.equilliumbio.com
  • 2223 Avenida De La Playa Suite 105
    La Jolla, CA USA 92037
  • Phone: 858.412.5302

Executives

Name Title Contact Details

Funding

Equillium raised $30M on 02/04/2021

Similar Companies

Quadrant Biosciences

Quadrant Biosciences is an epigenetic diagnostics company with a focus on the early detection of neurological disorders and other large-scale health issues. Revolutionary advancements in the early detection of autism spectrum disorder, Parkinson’s disease, and mTBI, through the application of the Clarifi® epigenetic diagnostic platform, could have a significant impact on the way clinicians approach the diagnosis and treatment of these serious conditions. In March 2020, we made the decision to pivot and allocate some of our resources to directly address the pandemic. By leveraging our expertise in RNA analysis, we have been able to be part of three exciting COVID-19 projects to aid in the detection of COVID-19 in individuals and communities across the U.S.

Biospec Products

Biospec Products is a Bartlesville, OK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kinnos

Our patented and award-winning Highlight® technology makes it easy to use disinfectants correctly.

Arbutus Biopharma

Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases. Our current focus areas include Hepatitis B virus (HBV), SARS-CoV-2, and other coronaviruses. To address HBV, we are developing a RNAi therapeutic, an oral PD-L1 inhibitor, and an oral RNA destabilizer to potentially identify a combination regimen with the aim of providing a functional cure for patients with chronic HBV by suppressing viral replication, reducing surface antigen and reawakening the immune system. We believe our lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening. It is currently being evaluated in multiple phase 2 clinical trials. We also have an ongoing drug discovery and development program directed to identifying novel, orally active agents for treating coronavirus (including SARS-CoV-2). In addition, we are exploring oncology applications for our internal PD-L1 portfolio.

The Hamner Institutes for Health Sciences

The Hamner Institutes for Health Sciences is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.